Nevisense

from Wikipedia, the free encyclopedia

Nevisense (manufacturer's name of the Swedish company SciBase AB) is a device for the early detection of black skin cancer , which is based on electrical impedance spectroscopy (EIS) and supplements classic diagnostic options. This method could increase the detection rate and reduce the number of unnecessary excisions . The EIS is one of the new procedures for improving existing diagnostic methods.

In Germany, the EIS is not a statutory health insurance service.

functionality

The system may in addition to the clinical and incident light microscopy in conspicuous moles and moles can be used. The skin is moistened and the electrical resistance and reactance are measured several times with an attached electrode at various (imperceptible) alternating current frequencies of 1 kHz - 2.5 MHz. This is designed to detect changes in the structure, alignment, size and type of skin cells to a depth of 2.5 mm below the skin surface, regardless of pigment or other optically visible features. The measurement results are converted into a score system from 0 to 10; Scores> 4 are assessed as positive (suspicious for cancer).

Importance for skin cancer diagnosis

The standard procedures currently include dermatoscopy , sequential digital dermatoscopy and automated whole-body photography. The need for supporting examination methods led to the establishment of new processes such as confocal laser scanning microscopy , Raman spectroscopy or electrical impedance spectroscopy. The accuracy of the EIS was examined in a study on melanoma detection in which almost 2000 patients took part: the sensitivity was 97%. This makes the EIS more reliable than the 7-point check and the ABCDE rule , with which six out of ten tumors can be diagnosed. The specificity was 38%, the negative predictive value, i.e. the measure for the reliability in the case of negative findings, is 99%. This may help reduce unnecessary removal of moles. In a study in which the combination of EIS and digital dermatoscopy was examined, the measured sensitivity was 100% and the specificity was 69.5%.

Possibilities and limits

The impedance on which the Nevisense measurement is based can vary due to interfering factors such as humidity, high exposure to sunlight and seasonal factors. In addition, the system is imprecise for wounds and fibrosis and should not be used for such skin changes. There are therefore users who request more studies before the method can be used on a larger clinical scale. In more recent publications, however, the EIS is viewed as sufficiently scientifically proven.

Individual evidence

  1. ↑ Julia Welzel, Elke Sattler (Hg): Non-invasive physical diagnostics in dermatology. Springer-Verlag Berlin Heidelberg (2016), p. 96 ff. Online access on February 16, 2017.
  2. ↑ C. Fink, H. Haenssle: Strategies for the non-invasive diagnosis of melanoma. In: hautnah (2016). Accessed online on February 16, 2017.
  3. ↑ J. Malvehy et al .: Clinical performance of the Neivsense system in cutaneaous melanoma detection: an international, multicentre, prospectivfe and blinded clinical trial on efficacy and safety. In: British Journal of Dermatology (2014). Accessed online on February 16, 2017.
  4. ^ Munich TV. Online access ( memento of February 18, 2017 in the Internet Archive ) on February 16, 2017.
  5. ↑ Julia Welzel, Elke Sattler (Hg): Non-invasive physical diagnostics in dermatology. Springer-Verlag Berlin Heidelberg (2016), p. 96 ff. Online access on February 16, 2017.
  6. ^ L. Rocha, S. Menzies et al .: Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesions. In: British Journal of Dermatology (2017) Accessed online 5 February 2020.
  7. ↑ Takashi Nagaoka: Recent Advances in Diagnostic Technologies for Melanoma. In: Advanced Biomedical Engineering (2016). Accessed online on February 16, 2017.
  8. ^ Website of the International Society of Digital Imaging of the Skin. Online access ( memento of February 17, 2017 in the Internet Archive ) on February 16, 2017.
  9. ↑ Anand Rotte, Madhuri Bhandaru: Immunotherapy of Melanoma. Springer International Publishing Cham (2016), p. 26. Accessed online on February 16, 2017
  10. ↑ Julia Welzel, Uwe Reinhold: EIS: precisely measuring atypia of skin changes. In: Der Deutsche Dermatologe 2018; 66 (11) Online access on February 5, 2020.
  11. ↑ C. Kellner, U. Reinhold: Modern diagnostic methods in dermatooncology. In: The Pathologist (2015). Accessed online on February 16, 2017.